O09047
PR
Gene name |
C3ar1 (C3r1) |
Protein name |
C3a anaphylatoxin chemotactic receptor |
Names |
C3AR, C3a-R, Complement component 3a receptor 1 |
Species |
Mus musculus (Mouse) |
KEGG Pathway |
mmu:12267 |
EC number |
|
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
1 structures for O09047
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-O09047-F1 | Predicted | AlphaFoldDB |
38 variants for O09047
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs220174002 | 5 | D>A | No | EVA | |
| rs240252246 | 5 | D>N | No | EVA | |
| rs3388854250 | 29 | I>N | No | EVA | |
| rs3388836468 | 35 | L>Q | No | EVA | |
| rs3388852382 | 112 | L>P | No | EVA | |
| rs3413100839 | 129 | W>* | No | EVA | |
| rs3412961545 | 145 | C>Y | No | EVA | |
| rs3388852389 | 153 | M>L | No | EVA | |
| rs3388836480 | 159 | V>A | No | EVA | |
| rs234439976 | 180 | R>G | No | EVA | |
| rs215974468 | 188 | V>M | No | EVA | |
| rs245432061 | 191 | L>P | No | EVA | |
| rs3388864076 | 192 | S>N | No | EVA | |
| rs3388859005 | 196 | S>R | No | EVA | |
| rs3388858999 | 200 | D>G | No | EVA | |
| rs3388860685 | 204 | A>T | No | EVA | |
| rs3388860742 | 207 | T>I | No | EVA | |
| rs232252692 | 224 | Y>H | No | EVA | |
| rs213948456 | 225 | F>L | No | EVA | |
| rs254532241 | 228 | V>I | No | EVA | |
| rs3388860282 | 263 | V>I | No | EVA | |
| rs266239047 | 277 | R>H | No | EVA | |
| rs254251687 | 284 | A>T | No | EVA | |
| rs259551897 | 307 | D>N | No | EVA | |
| rs3388856751 | 320 | N>S | No | EVA | |
| rs3388859402 | 343 | F>S | No | EVA | |
| rs3388839200 | 360 | N>I | No | EVA | |
| rs3388842519 | 370 | R>L | No | EVA | |
| rs3397368579 | 383 | W>R | No | EVA | |
| rs3397366656 | 387 | H>N | No | EVA | |
| rs3388860353 | 387 | H>Q | No | EVA | |
| rs3397360135 | 392 | L>Q | No | EVA | |
| rs3388822168 | 401 | S>E | No | EVA | |
| rs3388839266 | 401 | S>F | No | EVA | |
| rs3388847394 | 417 | A>V | No | EVA | |
| rs264217181 | 460 | N>S | No | EVA | |
| rs3388858948 | 472 | N>K | No | EVA | |
| rs3388856748 | 478 | V>K | No | EVA |
No associated diseases with O09047
1 regional properties for O09047
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| domain | GPCR, rhodopsin-like, 7TM | 40 - 428 | IPR017452 |
2 GO annotations of cellular component
| Name | Definition |
|---|---|
| integral component of membrane | The component of a membrane consisting of the gene products and protein complexes having at least some part of their peptide sequence embedded in the hydrophobic region of the membrane. |
| plasma membrane | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. |
4 GO annotations of molecular function
| Name | Definition |
|---|---|
| complement component C3a binding | Binding to a C3a product of the complement cascade. |
| complement component C3a receptor activity | Combining with the C3a product of the complement cascade and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. |
| complement receptor activity | Combining with any component or product of the complement cascade and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. |
| G protein-coupled receptor activity | Combining with an extracellular signal and transmitting the signal across the membrane by activating an associated G-protein; promotes the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G-protein complex. |
16 GO annotations of biological process
| Name | Definition |
|---|---|
| chemotaxis | The directed movement of a motile cell or organism, or the directed growth of a cell guided by a specific chemical concentration gradient. Movement may be towards a higher concentration (positive chemotaxis) or towards a lower concentration (negative chemotaxis). |
| complement receptor mediated signaling pathway | The series of molecular signals generated as a consequence of a component of the complement pathway binding to a complement receptor. Such components include both whole complement proteins and fragments of complement proteins generated through the activity of the complement pathway. |
| inflammatory response | The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. |
| phospholipase C-activating G protein-coupled receptor signaling pathway | A G protein-coupled receptor signaling pathway in which the signal is transmitted via the activation of phospholipase C (PLC) and a subsequent increase in the intracellular concentration of inositol trisphosphate (IP3) and diacylglycerol (DAG). |
| positive regulation of angiogenesis | Any process that activates or increases angiogenesis. |
| positive regulation of cell migration | Any process that activates or increases the frequency, rate or extent of cell migration. |
| positive regulation of cytosolic calcium ion concentration | Any process that increases the concentration of calcium ions in the cytosol. |
| positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway | Any process that increases the concentration of calcium ions in the cytosol that occurs as part of a PLC-activating G protein-coupled receptor signaling pathway. G-protein-activated PLC hydrolyses phosphatidylinositol-bisphosphate (PIP2) to release diacylglycerol (DAG) and inositol trisphosphate (IP3). IP3 then binds to calcium release channels in the endoplasmic reticulum (ER) to trigger calcium ion release into the cytosol. |
| positive regulation of DNA biosynthetic process | Any process that activates or increases the frequency, rate or extent of DNA biosynthetic process. |
| positive regulation of glomerular mesangial cell proliferation | Any process that increases the frequency, rate or extent of glomerular mesangial cell proliferation. |
| positive regulation of macrophage chemotaxis | Any process that increases the rate, frequency or extent of macrophage chemotaxis. Macrophage chemotaxis is the movement of a macrophage in response to an external stimulus. |
| positive regulation of neutrophil chemotaxis | Any process that increases the frequency, rate, or extent of neutrophil chemotaxis. Neutrophil chemotaxis is the directed movement of a neutrophil cell, the most numerous polymorphonuclear leukocyte found in the blood, in response to an external stimulus, usually an infection or wounding. |
| positive regulation of smooth muscle cell proliferation | Any process that activates or increases the rate or extent of smooth muscle cell proliferation. |
| positive regulation of vascular endothelial growth factor production | Any process that increases or activates the frequency, rate, or extent of production of vascular endothelial growth factor. |
| regulation of blood pressure | Any process that modulates the force with which blood travels through the circulatory system. The process is controlled by a balance of processes that increase pressure and decrease pressure. |
| tolerance induction to nonself antigen | Tolerance induction in response to nonself antigens. |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MESFDADTNS | TDLHSRPLFQ | PQDIASMVIL | GLTCLLGLLG | NGLVLWVAGV | KMKTTVNTVW |
| 70 | 80 | 90 | 100 | 110 | 120 |
| FLHLTLADFL | CCLSLPFSLA | HLILQGHWPY | GLFLCKLIPS | IIILNMFASV | FLLTAISLDR |
| 130 | 140 | 150 | 160 | 170 | 180 |
| CLIVHKPIWC | QNHRNVRTAF | AICGCVWVVA | FVMCVPVFVY | RDLFIMDNRS | ICRYNFDSSR |
| 190 | 200 | 210 | 220 | 230 | 240 |
| SYDYWDYVYK | LSLPESNSTD | NSTAQLTGHM | NDRSAPSSVQ | ARDYFWTVTT | ALQSQPFLTS |
| 250 | 260 | 270 | 280 | 290 | 300 |
| PEDSFSLDSA | NQQPHYGGKP | PNVLTAAVPS | GFPVEDRKSN | TLNADAFLSA | HTELFPTASS |
| 310 | 320 | 330 | 340 | 350 | 360 |
| GHLYPYDFQG | DYVDQFTYDN | HVPTPLMAIT | ITRLVVGFLV | PFFIMVICYS | LIVFRMRKTN |
| 370 | 380 | 390 | 400 | 410 | 420 |
| FTKSRNKTFR | VAVAVVTVFF | ICWTPYHLVG | VLLLITDPES | SLGEAVMSWD | HMSIALASAN |
| 430 | 440 | 450 | 460 | 470 | |
| SCFNPFLYAL | LGKDFRKKAR | QSIKGILEAA | FSEELTHSTN | CTQDKASSKR | NNMSTDV |